文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

抗IL-6治疗对真性红细胞增多症小鼠模型的血细胞比容及脾大无改善作用

Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.
PubMed 文献 · Blood Adv · 2022-01-01

本研究在JAK2-V617F敲入小鼠中给予抗IL-6抗体或IgG对照治疗三周,评估其对炎症因子、血细胞比容和脾大的影响。结果显示抗IL-6治疗显著降低CXCL2和CXCL10等血清炎症因子,但未降低升高的血细胞比容、红细胞和白细胞计数,脾大及脾脏组织病理也未见明显改善。

要点

  • 抗IL-6抗体可调节JAK2-V617F小鼠的血清炎症因子谱。
  • 抗IL-6治疗未降低血细胞比容、红细胞及白细胞计数。
  • 脾大和脾脏组织病理未见明显改善。

核心结论

  • 抗IL-6抗体治疗未能改善JAK2-V617F小鼠的血液学疾病参数,但可调节血清炎症因子谱。

研究设计与样本

  • JAK2-V617F敲入小鼠(JAK2+/V617F)接受抗IL-6抗体或IgG对照治疗三周。
  • 检测血清炎症因子、血细胞比容、血细胞计数、脾大及脾脏组织病理。

主要发现

  • 抗IL-6抗体治疗后血清CXCL2和CXCL10水平显著降低。
  • CXCL1、CCL11、M-CSF、G-CSF、IL-17、IL-12p40和CCL2降低至原来的0.3–0.8倍,部分变化在高剂量IgG组亦出现。
  • JAK2+/V617F小鼠血细胞比容、红细胞和白细胞计数升高,抗IL-6抗体未使其降低。
  • 脾大和脾脏组织病理未见明显改善。

局限性

  • 研究为小鼠模型,结论外推至真性红细胞增多症患者需谨慎。
  • 仅治疗三周,未评估更长疗程或联合治疗的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations in JAK2, MPL and Calreticulin and inflammation play a key role in pathophysiology of chronic myeloproliferative neoplasia (CMN). One of the most prominent cytokines elevated in serum of Polycythemia vera patients is interleukin-6 (IL-6). Currently, it is being discussed whether suppression of inflammation by anti-cytokine approaches as anti-IL-6 treatment may be therapeutically useful in CMN. We here sought to investigate the efficacy of anti-IL-6 treatment on inflammatory cytokines, hematocrit and splenomegaly in CMN like disease. JAK2-V617F knock-in mice (JAK2+/V617F) were treated for three weeks with anti-IL-6 antibody (Ab) or IgG-control. Upon anti-IL-6 Ab treatment, serum levels of CXCL2 and CXCL10 were significantly reduced. In addition, CXCL1, CCL11, M-CSF, G-CSF, IL-17, IL-12p40 and CCL2 were reduced by a factor of 0.3 -- 0.8. Partly, this was also achieved by applying high-dose IgG. Hematocrit, erythrocyte and leukocyte counts were elevated in JAK2+/V617F mice but were not reduced by anti-IL6 Ab treatment. In addition, there was no apparent amelioration of splenomegaly and spleen histopathology. In conclusion, anti-IL-6 Ab treatment did not result in improvement of hematological disease parameters but was shown to modulate the serum cytokine signature.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Baldauf CK, Müller P, Haage TR, et al. Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model. Blood Adv. 2022. PMID: 34559181. doi:10.1182/bloodadvances.2021004379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。